Illumina, Inc. (ILMN) Earnings Call Transcript & Summary

October 29, 2020

NASDAQ US Health Care Life Sciences Tools and Services earnings 59 min

Earnings Call Speaker Segments

Juliet Cunningham

executive
#1

Good afternoon, everyone, and thank you for being with us on this conference call covering the results of our third quarter of 2020. On today's call, we're going to go over the financial results that were published following the market's close, and we'll also provide commentary regarding our commercial activity, and after that we'll open things up for a question-and-answer session. Should you not yet have looked at the earnings release, you can locate it within the Investor Relations portion of our site, illumina.com. Here for Illumina today are Francis deSouza, our President and Chief Executive Officer, along with Sam Samad, our Chief Financial Officer. Francis is going to give an update regarding our business, and Sam is going to walk through our financial results. Just like we did last quarter, we're hosting this call from several different locations. So please be patient with us should any technical problems or pauses arise. This call is being recorded, and the audio portion is going to be archived within the Investors Section of our site. It is our intention that any forward-looking statements about our financial results and commercial activity that get made on today's call will be protected under the Private Securities Litigation Reform Act of 1995. Forward-looking statements carry risks and uncertainties. Actual events or results could differ materially from what is projected or discussed. Every forward-looking statement is based on information currently available, and Illumina takes on no obligation to update these statements. To gain a better understanding of the risks and uncertainties that might cause actual results to differ, we point you to the document that Illumina files with the Securities and Exchange Commission, including Illumina's most recent Forms 10-Q and 10-K. With that, I'll turn the call over to Francis.

Francis deSouza

executive
#2

Thanks, Juliet. Hello, everyone, and I appreciate you being with us this afternoon. In Q3, our business bounced back strongly, recovering more quickly than anticipated among both clinical and research clients. Revenue for the third quarter totaled $794 million, which represents a 26% increase from the previous quarter and a 12% decline versus the same period a year ago. I'll walk through the quarter's top developments, and Sam will go deeper into the financial details. Sequencing revenue rose 25% from the second quarter of 2020. Sequencing consumables were up 29% quarter over quarter, with momentum across our high, mid, and low throughput offerings. NextSeq's momentum kept building, as mid throughput consumables advanced both sequentially and 3% year over year, and we anticipate further growth in Q4. Sequencing instruments likewise beat expectations, with revenue climbing 24% from the prior quarter. This increase came mainly from more shipments of NovaSeq and NextSeq platforms. NovaSeq purchases have made a nice comeback since Q1, when some customers put off buying as shelter-in-place policies kicked in; we're happy with how NovaSeq shipments have grown quarter over quarter since Q1. We head into the fourth quarter with a robust NovaSeq pipeline and expect that sequential growth to carry on in Q4. Beyond that, we enjoyed another strong quarter for our mid throughput lineup, with NextSeq 2000 and NextSeq 550 both surpassing our expectations. Robust demand for these adaptable sequencers produced record mid throughput shipments during the third quarter; we're particularly encouraged by how well the NextSeq 2000 launch has gone, given positive customer response and demand. Roughly one-third of NextSeq 2000 placements come from customers new to Illumina. As we anticipated, we've observed minimal cannibalization of NovaSeq conversions among the remaining HiSeq customers. Sequencing service and other revenue rose 9% sequentially and came in 28% below the prior year, because of one-time IVD licensing and development revenue exceeding $30 million in last year's third quarter. Total Microarray revenue reached $86 million, rising 28% sequentially as direct-to-consumer customers and other applications started to bounce back from pandemic-related headwinds. Now to our customer segments. We observed meaningful gains in both clinical and research activity. As a reminder, we monitor sequencing run rate as a gauge of overall activity. Run volumes rely on sampling and don't directly tie to revenue. The purpose of sharing this metric is to help investors grasp customer sequencing activity. Clinical sequencing run volumes climbed from an average of 84% in Q2 to 96% in Q3 relative to pre-pandemic levels. In oncology, we're heartened by indications pointing to continued NGS adoption in cancer treatment. The European Society for Medical Oncology, or ESMO, became the first scientific society to release recommendations for using NGS in oncology. Depending on the cancer type, the society recommends NGS for large multi-gene panels to determine tumor mutation burden and to screen patients for clinical trials. At this point in time, TSO 500 — intended solely for research purposes — offers thorough genomic profiling and roughly 250 customers have taken it up. We’re thrilled to bring out a CE-IVD-marked TSO comprehensive assay during 2021, so labs may adhere to ESMO guidelines and keep enhancing results for cancer patients. Expanding payer choices will keep widening how available these tests become. Aetna, which covers 19 million lives, said last month it would cover large-panel comprehensive genomic profiling for solid as well as liquid cases, including TMB testing. We also take encouragement from greater availability and uptake of NGS-based liquid biopsy testing. The latest FDA clearance for Guardant360 and FoundationOne Liquid CDx shows these technologies’ clinical utility — they find cell free DNA from the tumor in blood and can deliver comprehensive genomic profiling plus tumor tissue when that isn’t obtainable. Panels like these liquid biopsy options open access wider for more patients who stand to gain from NGS in their cancer care. Reproductive health delivered strength this quarter, rising both sequentially and year-over-year. Indeed, in the third quarter reproductive health averaged above 100% of its pre-pandemic run rate; we anticipate ongoing growth since reimbursement prospects have never appeared more favorable. ACOG recently revised its guidance to advise that NIPT be offered to every pregnant woman, no matter her maternal age or baseline risk. That’s a significant milestone, and we expect payers to keep following ACOG’S guidance, which adds to the already $130 million plus lives covered for average risk within the U.S. Centene, for instance, recently brought its guidelines into line, extending average risk coverage to another 23 million lives in the U.S. Centene also ranks as the biggest Medicaid managed care organization in the U.S. That means this coverage choice will make NIPT an option available to more medically underserved areas and populations. In genetic disease testing, doctors, insurance companies and governments worldwide are increasingly turning to sequencing to diagnose children suspected of having genetic conditions. We see solid movement on the reimbursement side. Payer adoption across the U.S. keeps expanding. With more than twice the lives covered for whole genome sequencing compared with the year’s start. And Australia recently stated it will reimburse whole exome or genome sequencing to pinpoint the genetic cause of intellectual disabilities; these favorable developments give us confidence along with sustained long term growth in this under penetrated market. Shifting to research, sequencing runs display continued gains, climbing from an average of 65% in the second quarter to 82% in the third quarter, relative to its pre-pandemic run volumes. We’re encouraged to watch researchers come back to their labs and reopen, and this degree of improvement surpassed our expectations. In research, we’re watching NGS’s role take shape within infectious disease. We think the most probable near term use case for sequencing lies in research and surveillance for efforts such as Australia’s first national COVID-19 tracking system, which seeks to sequence the virus genomes of all positive COVID-19 tests in Australia. And monitor COVID-19 through genomics nationwide. The NIH is boosting the money it allocates toward comprehending COVID-19 as well as how the virus spreads, through genomic testing. Our view remains that PCR and antigen tests will handle the bulk of COVID-19 testing, while NGS adds extra capacity. Because of that, we are not counting on any meaningful revenue impact during Q4 coming from COVID-19 testing. Turning to population genomics, encouraging movement is visible. In Q2, All of Us obtained its IDE approval from the FDA. Samples, as anticipated, began moving from the Biobank over to partner genome centers. We anticipate the project scaling up in Q4 and continuing into 2021. Sequencing work for the UK Biobank carried on through Q3, and we anticipate a gradual return to typical volumes with sequencing persisting into 2021; additionally, we anticipate whole genome sequencing services for the NHS genomic medicine service kicking off later in this quarter. Since the NHS is presently concentrated on COVID, we anticipate this program ramping up gradually across the coming few quarters. Possibly the most pandemic-resistant popGen program has been the Million Veteran Program, or MVP. Its goal is delivering understanding of how genetics, lifestyle and military exposures influence health and wellness.

Francis deSouza

executive
#3

Also, it has just widened the scope of who it aims to enroll, going from 1 million veterans to 2 million. Through a sequencing partner, the U.S. Department of Veterans Affairs expects to pass the hundred thousand whole genome milestone prior to the year's end. Our markets should grow because of these efforts and others, and we think exciting new opportunities will emerge for Illumina. We remain dedicated to staying at the forefront of innovation through fresh product introductions that back the markets and customers we support, among them NovaSeq 6000 version 1.5 agents, which came out in the third quarter. What this release provides is greater shelf life, better quality scores, longer indices, and above all, it widens access to the $600 genome so smaller labs can succeed, while giving labs more reason to move up from Hiseq to NovaSeq. Customer response to NovaSeq 6000 version 1.5 reagents has been very strong. Take, for instance, the princess Maximus Center, Europe's biggest national pediatric oncology center, which had been sending its genome sequencing out to a collaborator. With these new reagents, though, they could buy a NovaSeq and are now able to begin doing testing internally, which means genomic information that may change care could get to children with cancer sooner and be handled nearer to the patient. The Canadian biotech company can adopt the Novaseq 6000 for creating antibody products for a potential COVID-19 therapy, thanks to the longer read lines paired with high throughput scale. This quarter, we are getting ready to introduce NextSeq 1000. With NextSeq 1000, customers doing lower throughput can take up our newest platform as an entry point, with the option to field upgrade during the NextSeq 2000. This quarter we are also bringing out the P3 flow cells. Academic core labs and other Early Access P3 customers already rely on the flow cell for routine sequencing methods in mid sized research projects, which allows quicker turnaround times. P3 is being used by other customers to build workflows in single cell epigenetics and spatial transcriptomics. These illustrate how, amid these difficult times, we keep carrying out our present and future plans to further our mission and build long term shareholder value. I'll now turn the call over to Sam to go over the third quarter financials.

Sam Samad

executive
#4

Thanks, Francis. As we discussed, revenue for the third quarter of 2020 came in at $794 million, which is a 12% decline year-over-year but a 26% increase versus the second quarter of 2020. The global pandemic kept affecting our business, yet we observed encouraging recovery signals among both clinical and research customers. Sequencing consumables revenue reached $500 million, rising 29% sequentially and falling 5% compared with the prior year period. The quarter-over-quarter growth of $113 million showed meaningful improvement across high-, mid- and low-throughput platforms, and NovaSeq pull-through came back to over 1 million per system per year. Our mid-throughput sequencing consumables increased in the quarter relative to the same period last year. Total sequencing system revenue was $109 million, ahead of our expectations, as both NovaSeq and our mid-throughput platforms beat what we expected at the start of the quarter. The third quarter also set a record for mid-throughput shipments, fueled by customer demand for NextSeq 2000 and the NextSeq 550Dx platform. In fact, NextSeqDx shipments accounted for over 40% of NextSeq 550 shipments year-to-date. Since 2013, Illumina has shipped more than 1,000 Dx instruments, which reflects the increasingly clinical nature of our customer base. Sequencing service and other revenue came to $99 million, lower than in the third quarter of 2019. Total sequencing revenue was $708 million, representing 89% of total revenue. Lastly, total microarray revenue of $86 million declined 16% from the third quarter of 2019, reflecting lower consumables and services revenue, mainly because of COVID-19-related headwinds. Now to the regions. Americas' revenue of $436 million exceeded expectations and rose over $100 million, or 30%, compared with the second quarter of 2020. That sequential growth came from both research and clinical customers, as labs continued reopening and clinical activity picked up. In fact, clinical sequencing consumables grew modestly versus the prior year period, as demand began recovering after testing delays in the second quarter. EMEA revenue of $213 million was up $45 million compared with the second quarter of 2020, with strength in sequencing consumables, which grew relative to the third quarter of 2019, driven by a strong rebound among both clinical and research customers. China revenue grew sequentially to $83 million, driven by strength in instrument placements. APJ revenue was roughly flat year-over-year at $62 million and rose $11 million compared with the second quarter of 2020, with NIPT helping to lead the recovery through sequential and year-over-year growth. Moving through the P&L. I will highlight non-GAAP results that include stock-based compensation. I encourage you to review the GAAP reconciliation of these non-GAAP measures, which can be found in today's release and the supplementary data available on our website. Please note that all subsequent references to net income and earnings per share refer to the results attributable to Illumina shareholders. Non-GAAP gross margin of 67.4% was lower as expected on both a year-over-year and sequential basis. The drop compared with a year earlier came from IVD partnership revenue in Q3 2019 that did not recur this year, along with reduced volume and elevated freight costs tied to the pandemic. Non-GAAP operating expenses reached $365 million, above both the second quarter of 2020 and the same quarter a year ago. As expected, sequential growth came from more spending on R&D projects and higher compensation expenses. Versus the third quarter of 2019, operating expenses rose mainly because of compensation-related costs and greater project spend, partly offset by less travel. Non-GAAP operating margin came in at 21.4%, compared with 15.8% in the prior quarter. The non-GAAP tax rate was 14.8%, below both last quarter and the prior year, thanks to discrete tax benefits tied to prior year return adjustments and the release of tax reserves. GAAP net income for the third quarter of 2020 was $179 million, or $1.21 per diluted share, while non-GAAP net income was $150 million, or $1.02 per diluted share. Other income largely explains the gap between GAAP and non-GAAP net income, reflecting net gains from mark-to-market adjustments on our strategic investments, chiefly our marketable equity securities. Also in the third quarter, cash flow from operations totaled $153 million, capital expenditures were $48 million, and free cash flow came to $105 million. DSO was 53 days versus 55 days in the prior quarter, partly because of stronger collections. During the third quarter we bought back $125 million of common stock, leaving $295 million available for repurchase under our current plans. We closed the quarter with roughly $3.3 billion in cash, cash equivalents and short-term investments. Our weighted average diluted share count for the quarter was about 148 million. As we keep navigating this pandemic, uncertainty remains around virus resurgence and the pace of recovery, so we will not offer guidance for the rest of the year. We are also watching pandemic developments closely, given the risk of further shutdowns in the U.S. and Europe. In the fourth quarter, we expect sequencing run volumes for clinical and research customers to keep improving modestly from the 96% and 82% levels, respectively, seen in the third quarter. Again, we caution this does not directly correlate to revenue, but third quarter data indicates customers are steadily returning to their labs, which will drive increased activity. Consistent with the third quarter, we expect fourth quarter sequential growth across all regions, with China and APJ showing flat to modest growth year-over-year. For the fourth quarter of 2020, we currently expect continued sequential revenue improvement, driven by sequencing consumables rising modestly on a sequential basis as clinical and research activity keeps gradually improving. Sequencing instruments are increasing sequentially, and the fourth quarter is expected to be the year's strongest quarter for instrument placements. On a sequential basis, sequencing service and other will be flat, while microarrays should rise modestly as we keep seeing a gradual recovery in direct-to-consumer and genotyping applications. Turning to the remainder of the P&L, we anticipate a sequential decline in non-GAAP gross margin, partly because of product mix with a bigger contribution from instrument sales, and a sequential increase in non-GAAP operating expenses, mainly from R&D project-related expenses, compensation-related expenses, and an extra week in the fourth quarter versus both the prior quarter and the prior year. Non-GAAP EPS should be roughly flat against the third quarter of 2020, reflecting revenue improvement offset by lower gross margins plus the sequential rise in operating and tax expenses. With that, I'll turn the call back to Francis for some closing remarks.

Francis deSouza

executive
#5

Thank you, Sam. Since we lead the world in sequencing platforms and consumables, our offerings have made it possible for pioneering research efforts and game-changing clinical assays to emerge, and those hold the promise of altering how patients are cared for. Among the biggest chances we have to affect patients and to generate revenue in the years ahead is using NGS to find cancer at an early stage. Last month, we said we had reached a definitive agreement to purchase GRAIL, and we anticipate that deal will be completed during the second half of 2021. Our planned buy of GRAIL, we believe, will usher in a new period of detecting cancer early, change survival outcomes for cancer, and unlock the broadest clinical use of genomics that we have witnessed. Once the acquisition is done, we can't wait to bring our GRAIL coworkers into Illumina. After closing, our plan is for GRAIL to run as a division inside Illumina. We stay dedicated to backing every one of Illumina's customers and to making sure that those innovators wanting to build NGS based tests keep getting access to our technologies. To wrap up, our business's rebound picked up speed during the third quarter, with notable growth in sequencing consumables revenue relative to the second quarter of 2020; and we anticipate that consumables will keep growing in the fourth quarter. Just as importantly, we are advancing well in embedding genomics into the standard of care, across oncology therapies, selection, NIPT, and genetic disease testing. And above all, we feel we are building a solid base for Illumina's growth both near term and long term. With that, we'll start the Q&A.

Doug Schenkel

analyst
#6

Afternoon, everyone, and thanks for letting me ask. This quarter obviously came in ahead of what most people were looking for. Honestly, it seems like it beat what you folks likely anticipated too, in plenty of cases. What I want to know is whether you can gauge how much of that came from playing catch-up as opposed to representing a fresh starting point we grow from here. Judging by what you both said in your prepared remarks about Q4 — Sam, and you too, Francis — it sounds like this is more of a fresh starting point, given the momentum you described going into Q4. Would that be accurate?

Francis deSouza

executive
#7

Hello, Doug. Yeah, I'd say that's accurate. When we consider the way the quarter unfolded, it definitely came out ahead of what we'd anticipated, judging by how those opening weeks of the quarter appeared; so what emerged as the quarter progressed was a speeding up of the rebound when it came to sequencing activity among both our clinical and research customers. And so, once we closed out the quarter, I believe we've landed at a fresh baseline that we'll carry into Q4. So I'd say it's accurate that the rebound sped up and formed a fresh baseline for us moving ahead.

Tycho Peterson

analyst
#8

Hey, thanks. There are two areas I'd like to touch on. First, the elasticity tied to the consumable price reduction — you mentioned a few cases, like customers who stepped up because of the $600 genome and pointed to that as their rationale for purchasing. But looking toward the coming year, how much additional demand do you believe this will generate? And how much will it spur the projects you were hoping it would? Then on the instrument side, instruments remain down 23%? Could you share some thoughts on when you expect them to return to growth?

Francis deSouza

executive
#9

Yes, sure. Let me address both. Starting with elasticity, which relates to the Version 1.5 Reagent launch. What Version 1.5 sought to accomplish — and what we observed during the quarter — was that it truly spurred the smaller core labs by providing them with access to the $600 genome. The larger labs already had that access; so this release was aimed at the smaller core labs; and the goal is twofold. First, to unlock elasticity within that portion of the market. We saw customers contemplating larger projects. We saw customers shifting toward insourcing. I mentioned one such case during the prepared remarks. Second, this release was meant to spur an upgrade cycle within that segment — the smaller core labs; and we began seeing cases of customers who either owned older instruments or had none at all. That might mean HiSeq, for instance, or lacking sequencers entirely. Thanks to this release, they could purchase a Novaseq. Both of these dynamics — spurring demand elasticity through larger projects, plus driving upgrade cycles — should, we believe, keep unfolding through Q4 and into the following year. Usually, when a new price point enters the market, a lower one, there's initially a bit of a headwind. In this instance, we anticipate it will be quite brief, and that's what we're seeing, as both positive dynamics begin appearing very quickly. Your second question concerned instruments, and perhaps I'll begin and Sam, you can add to it. I noted during the prepared remarks that we witnessed strong activity on the instrument front. We were quite pleased that across the year, in Q2, NovaSeq shipments rose relative to Q1, and Q3 exceeded Q2. So we're still expecting NovaSeq shipment growth as this year goes on, building off where Q1 left us, and mid-throughput instruments also showed solid demand. Sam, perhaps I'll hand things to you for additional detail.

Sam Samad

executive
#10

Absolutely. In fact, we've felt good about how the sequencing instrument has done — both during Q3 and in terms of how well it held up throughout the pandemic. Our expectation is that there will be declines compared to a year earlier, particularly in light of the pandemic and with some hesitancy around buying instruments. That said, as we turn our attention to Q4, we anticipate growth, and instruments represent our best quarter of the year; we also anticipate that NovaSeq will grow on a sequential basis. And to be clear, when I refer to growth in Q4, I'm talking about instrument revenues on a sequential basis. Beyond that, the pipeline appears quite robust for NextSeq 2000 as well as for NovaSeq.

Derik De Bruin

analyst
#11

Hi, good afternoon. A few questions. First, clearly, operating expense saw a significant increase during the latter half of the year. When we look ahead, should we consider that carrying over into 2021—and perhaps even greater, once some of the T&E returns, once travel returns? And I suppose some of the negative questions. Regarding the NIPT space, could you help us understand how many women who had coverage under high risk were actually utilizing it? What I mean is, among women who qualified for high risk, how many actually proceeded to NIPT testing? The reason I'm asking is I'm attempting to gauge what penetration might look like if average risk coverage were to broaden. Just trying to get a feel for the dynamics and how we might think about the NIPT business growing. Thank you.

Francis deSouza

executive
#12

Yes. Perhaps I'll begin, and then Sam can provide some additional color as well. When it comes to operating expenses, our approach throughout the year has been to examine our operating expenses very carefully; and one thing we aim to do is ensure we keep safeguarding the high priority items we were focused on. That includes our rich innovation pipeline; so we've safeguarded our projects tied to upcoming products, along with certain long term investments in the business; so those we've safeguarded; but we've sought out other areas where savings could be made, some of which sort of naturally unfolded as the pandemic went on through decreased travel. For instance, I believe some of those, you're correct, will return next year. And so Sam will speak to that further; regarding NIPT, obviously, it's a very regional story. But in the U.S., for instance, you have fairly solid penetration when it comes to women who qualify for NIPT actually receiving it. So most women who qualify for the test do receive it as part of their pregnancy; and so, opening up that market in the average risk segment does represent meaningful upside when it comes to the actual demand for the test.

Sam Samad

executive
#13

Absolutely, Derik — on the OpEx side, let me tack on a few additional thoughts. And by the way, I appreciate the question. What I'd point out is that we've stayed remarkably disciplined and intensely focused when it comes to running our operating costs, while simultaneously — and this ties to what Francis said — making sure we never diminish our innovation, never harm our spending on innovation, and never affect our R&D pipeline. That said, through three quarters of the year, right up to the close of Q3, we came in roughly $150 million under our own internal budget on operating expense. So we've been quite cautious about how we manage those costs — we're sitting around 10% beneath. Looking ahead, sure, certain items will begin climbing again. For instance, as staff return to the lab, our R&D projects will start ramping back up. That trend carries into next year. And some costs, we hope, will rise as the pandemic hopefully lets up — travel being one example. Overall, though, I'd say we've been exceptionally diligent and disciplined about controlling our costs through today.

Puneet Souda

analyst
#14

Hey, Francis. Thank you. And Sam, I appreciate you giving your thoughts on the fourth quarter as well. So, first thing — very recently, literally in the past 24 hours, lockdowns went into effect in France and across Europe. Those kinds of restrictions could end up spreading. I'm just curious whether that possibility is reflected in what you're expecting for Q4. Also, do you think European customers will handle things more flexibly this time when it comes to running their research and diagnostic sequencing work, compared with how they did previously? I'd like to hear your view on that. And since sequencing run rates, which you earlier put at 96% of where they stood before the pandemic, might we end up seeing a different benchmark? Is that assumption already built into your guidance? Then — my second question, if I may, about GRAIL. A major question that came up last week — actually starting this week — concerns the way Illumina pursued the GRAIL acquisition, especially given another multi-cancer liquid biopsy deal announced this week. I completely understand these acquisitions have no revenue yet, but GRAIL seems to carry a much bigger valuation than thrive. So could you say more about whether anything regarding the total market opportunity for the pre pen cancer test, or the technical performance in the gallery, or the size of the studies, or anything else, is what gives you stronger conviction and justifies a higher valuation? Thank you.

Francis deSouza

executive
#15

Yes. Thank you, Puneet. I'll begin with what you asked about possible restrictions in Europe, and perhaps in the U.S. too. During our prepared remarks, we noted that we are watching this carefully. Naturally, all of us hope the pandemic comes under control; nevertheless, there are clearly signals out of Europe pointing to possible shutdowns, or at minimum tighter restrictions. So for the fourth quarter, we're keeping a close eye on it. We took it into account when shaping what we expect for Q4. In fact, we stated that clinical sequencing activity during Q3 reached 96% of pre pandemic levels. Research stood at 82% of pre pandemic levels, and our expectation is that each will pick up slightly, since we're genuinely following how the pandemic develops through Q4, rather than anticipating a bigger improvement than that. As for your separate point about customers adapting more? I believe they are indeed becoming somewhat more adaptable when it comes to coexisting with the virus — not that they aren't clearly remaining very careful and cautious about it; even so, if you consider, for example, how many labs, based on our Q3 data, are now either fully open or operating at some level. Roughly 90% of the labs, versus approximately 50% back in April — though that doesn't mean all 90% are running complete systems ahead and fully open. Rather, they're either completely open or operating with restrictions — that's around 90% of all labs worldwide. So they're steadily ramping back up, yet doing so cautiously, and our expectation takes that into account.

Sam Samad

executive
#16

Also, Puneet, let me address what you asked regarding GRAIL. We discussed how spotting cancer early is, by a wide margin, the biggest clinical use for genomics that we are probably going to witness across the coming 10 to 20 years. We also noted that our expectation is that this market will include numerous competitors. Since the opportunity is so big, and since we anticipate that competitors will pursue varied strategies — be it single cancer against multi cancer, or differing technology strategies — and without a doubt we have quite a few customers, among them Thrive and Exact, plus Freenome and Guardant and additional liquid biopsy companies such as Foundation Medicine, who we anticipate will have a part in this market moving forward. And we're going to keep backing every one of those customers moving forward. The thing that drew us toward GRAIL was the distinctive place it holds in that market, in the sense of being nearest to owning a commercial test. And in the sense of possessing performance characteristics in line with being nearest to owning a commercial test. So GRAIL intends to bring its test to market in the coming year. And that will probably position them as the initial competitor to enter the market. They've additionally carried out, by a wide margin, a few of the biggest clinical studies in that area. And so more than 100,000 individuals are enrolled in the studies they've conducted, and they've produced a fairly extraordinary bulk of data tied to their test; and beyond that, the performance characteristics of their tests are extremely robust. So for the 12 deadliest cancers, they achieve a sensitivity in the high 60% alongside a false positive rate below 1%, which genuinely amounts to a best-in-class product at this moment in the market. Another thing we appreciate is that they're the sole competitor right now holding FDA approval, in the sense of being able to conduct an IDE study to give results back to patients. And so they're collaborating with a few of the top health care systems, among them the Mayo Clinic, Cleveland, Oregon Health System, the Intermountain health system, Dana Farber, Sutter Health. And so their gallery test is already in the hands of physicians giving results back to patients as part of their study. And so possessing that FDA approval is likewise quite appealing. And all of that clearly played a role in the price tied to GRAIL.

Dan Arias

analyst
#17

Hey, good afternoon everyone, and thanks. Francis, regarding that All of Us sample that's supposed to start coming through during this quarter — is there a meaningful consumables forecast baked in for 4Q? And if that does get underway, do you expect it to be entirely sequencing? Or could genotyping also end up being part of it? And let me squeeze in one more quick question. You seem to be anticipating slight growth in China. Is that included in the 4Q outlook? Did you mention that on a year over year basis, there'd be a sequential increase there unlike anything we've witnessed in some time? So what's behind the confidence in that shift, I suppose back up into the mid $90 million range?

Francis deSouza

executive
#18

Yes. Let's begin with All of Us; for all of those, our expectation is that the All of Us samples will begin flowing to partner genome centers in Q4, and that we'll start to see both sequencing and genotyping activity. From where we sit, the actual revenue contribution in Q4 should be modest. Still, it's a really important step, since it positions us well for All of Us to scale up more significantly as we head into next year. So that means the setup, the workflow has been established and the machine is getting going. So again, a modest contribution in Q4, yet that's a significant step and we believe it positions us well as we head into next year. And then Sam, perhaps you could speak about China.

Sam Samad

executive
#19

Yeah. Dan, I appreciate the question. To start with, when it comes to China, we're anticipating what I'd describe as a roughly flat result compared with the same period last year in Q4. As we mentioned during the prepared remarks, for China and APJ we're looking at flat to slightly up; so specifically in China, it's about level performance versus a year ago; actually, in China, the clinical side has been robust so far this year and is expanding compared with last year. Research, as we've discussed on earlier calls, has taken a hit, clearly because of the pandemic, with some effort redirected toward PCR testing, plus the overall effect of that on research. Still, we're happy with how clinical has performed in China. Q3 also saw solid instrument placements in China, which is a good sign for upcoming activity. So, definitely pleased with the clinical results there. And that gives us confidence.

Tejas Savant

analyst
#20

Hey, everyone. Appreciate you making room for us. I've got a few things to ask, and they're aimed at both Francis and Sam. Regarding the sequencing consumables line, you included some destocking during the second quarter. Could a restocking effect of some kind have contributed to that 29% growth versus the prior quarter? Then on oncology, how do you view a possible bolus in Q4 and the first half of 2021, once the screenings that were missed start happening again?

Francis deSouza

executive
#21

Yes. Thank you, Tejas. On the question of stocking levels and restocking — yes, during Q2 we had certain customers who destocked, particularly in AMR, and that hurt our results in Q2. Our data hasn't shown us any rise in inventories or any restocking as we moved into Q3. So basically, what we've observed — and we examined this closely alongside many of our customers — is that they're purchasing in line with the demand they actually have, yet they haven't rebuilt inventories to offset some of the destocking that happened in Q2. We also don't anticipate any restocking in Q4. Based on the activity levels we monitor and by cross-checking that against revenues, it's clear they're essentially buying according to their demand, and they'll keep doing so.

Sam Samad

executive
#22

Now, turning to oncology. I believe you've raised a very significant issue. One of the terrible consequences of the pandemic, in my view, is that some individuals are simply not going to get cancer screenings. As a result, they're walking around while cancer grows inside them. I think two kinds of dynamics will unfold here. First, at some point there will need to be a catch-up, correct? Sadly, for those people, that means their cancer has advanced. But whether this shows up in Q4 or the following year, a catch-up will happen for those who haven't received a diagnosis yet. On top of that, the second dynamic unfolding is that we're observing blood-based tests actually performing better throughout the pandemic. So when we examine how the markets are behaving, service providers offering blood-based tests have evidence that their business is more resilient during the pandemic than service providers doing tissue-based analysis. Thus, one thing unfolding over the pandemic's course is that you're beginning to see an acceleration of blood as a sample type for cancer testing. So you're witnessing an acceleration in liquid biopsy growth, which we believe is a durable dynamic; and this isn't merely because of the pandemic, but we think it will keep unfolding in the years ahead.

Vijay Kumar

analyst
#23

Hi there. I appreciate you fielding my question. I've got two quick things, I think. First, perhaps I heard it wrong, but the big fail, deal close — does that land in the latter half of the coming year? And I'm wondering what we ought to assume regarding investments at this point. Then, thinking about system placements, since this is a razor blade model, could you maybe expand on how the smaller number of systems this year ought to translate into next year? I understand that comparisons for consumables are simpler. Would that make up for the systems decline this year? I'm interested to know.

Francis deSouza

executive
#24

Yeah; allow me to address the two of those, then provide a bit of color. Regarding GRAIL, indeed, our expectation is that the deal closes during the latter half of 2021, while we move through the regulatory review; we've discussed somewhat the dilution tied to GRAIL; but honestly, additional details will come your way once the deal closes; and once more, that's the latter half of 2021. When it comes to instrument placements, we — clearly, you're correct, it is a razor blade model. And that's the reason it matters — that's the reason the recovery we're witnessing in instrument placements after exiting Q1 has us so encouraged; and therefore the strength in NovaSeq placements for Q2, Q3, and definitely the pipeline, as we head into Q4, is quite significant. Likewise, the strength we're observing in the mid-throughput portion of the portfolio, particularly NextSeq, including the new NextSeq 2000, along with the 500 and the Dx boxes, is a positive indicator for us as we look toward next year.

Catherine Shelton

analyst
#25

Hi there. I appreciate you taking the questions. I suppose this is a two-part question regarding the GRAIL studies. When next year should we anticipate data from Pathfinder becoming available? Also, as you transition into an all comers screening population for that study, do you anticipate any decline in performance? Then for the second part, about the Thrive study: my understanding is that GRAIL finished enrolling patients in late 2018 and then tracked those patients over 30 months. So might we get a readout sometime next year, or is that more likely to land in 2022?

Francis deSouza

executive
#26

Yes. So regarding the GRAIL studies we discussed. The simple response is that for the Pathfinder study, we do not anticipate performance data that differs substantially from what has been observed to this point. The reason is that a number of other large scale studies have been conducted by GRAIL. For instance, 15,000 people were enrolled in the CCGA study. That study's second phase was a prospective study and all comers study. So considering how large that study was, they used the same test. The performance data published externally rests on statistically significant data. Therefore, we did not anticipate that Pathfinder data would show anything different. Actually, prior to signing the deal, a small group of people reviewed certain early results or the mid-term results tied to Pathfinder — and while we won't probably about that. Those results are generally consistent with our expectations. Consequently, we do not anticipate that the final study results published next year will differ significantly from the performance characteristics observed so far. What was the second part of that question?

Sam Samad

executive
#27

Francis, go ahead with Thrive.

Francis deSouza

executive
#28

Right. Thrive, then, is a prospective study — 100,000 women, and full enrollment happened roughly 18 months back. So it's — once more, quite a way along, and it moves quickly. And again, in the same way, because of how large the earlier studies were, what we anticipate is more confirmation regarding performance characteristics, with nothing markedly different.

Patrick Donnelly

analyst
#29

Thanks a lot. Maybe I'll ask about PopSeq. It's good to hear that some of the bigger projects are gaining traction and should begin contributing before long. Of course, the schedule has been pushed back several times already. With the revised fourth-quarter dates, particularly for All of Us, how confident are you that these will actually start on time? And do the expected paths look similar to what you outlined before? Take All of Us — near the beginning of the year, I believe you referenced 60,000 whole genomes across the initial half-year. Once things are underway, is the same trajectory still expected? Thanks.

Francis deSouza

executive
#30

Yeah, that's a fair question. When we consider our position regarding those population studies, let me address the four major ones. Specifically, those would be the UK Biobank, the million veterans, all of us, and the UK NHS. At present, as we move into next year, most of them are already established. It's simply a question of either returning them to their previous state—as is the case with the UK Biobank—or increasing sample volumes. Compared to where we stood a year ago, this is a far stronger position. Back then, everyone still needed to secure FDA clearance, and after that, we had to figure out the processes for moving samples to its partner genome centers. Taking them one by one, the UK Biobank came into the year sequencing at a high volume, then scaled back in March as a result of the pandemic, and now they are beginning to increase capacity again as we head into next year. So if things go well, we're quite confident they can scale fast. We've mentioned how the million veterans program stayed really strong all year and actually broadened what it covers during this year. Every one of us who gave samples—those are coming in during Q4. So really, next year is just about expanding, which is a solid position for actually launching it. As for the UK NHS this year, it's been paused, mainly because the NHS has been busy with the pandemic testing they're handling. They're also anticipated to begin sequencing during the current quarter. That, in our view, leaves us well positioned to witness expansion as we move into the following year. So with all four of them, we're quite confident that by the close of this year, each will be handling samples and prepared to ramp up while addressing the accumulated demand they've been sitting on.

Dan Leonard

analyst
#31

Thanks. I've got a pair of questions about expenses. First, could you give more detail on the gross margin line — what drove the sequential decline, and what's behind the additional decline you expect in the fourth quarter? Second, regarding the anticipated GRAIL acquisition, does it shift your philosophy in any way when it comes to budgeting for base Illumina as you head into 2021? Thank you.

Francis deSouza

executive
#32

Yes, Dan, thanks for asking. Let me start with gross margin. The drop from Q2 to Q3 was actually in line with what we had anticipated. Gross margin landed a bit above what we expected. The reasons were some extra items — we incurred additional freight costs, additional compensation costs within our operations group. Beyond that, some of the ramp on the project also added extra impact on gross margin, or on cost. So that matches our expectation. As for the Q4 decline relative to Q3, mix is really the main factor. We have a strong instrument quarter, and that outweighs some of the gains from consumables, so mix gets hurt by that. Now on expectations for 2021. When we consider the core business and Illumina, there really isn't a material shift in our budget, philosophy, and approach. We remain absolutely focused on continuing to invest in the core business, and also on delivering the shareholder returns we committed to for the core business, to keep driving and supporting that over time. At the same time, GRAIL presents a really compelling opportunity, and we're going to keep investing behind that opportunity. It will be dilutive in the next few years, but we're committed; so there's no major change to our budgeting philosophy for 2021 as it applies to the core business.

David Westenberg

analyst
#33

David, thanks for the question. We do value your long-term outlook regarding double-digit expansion in consumables and the way consumables are sequenced. Could you put a number on how much of that comes from clinical, and in particular, how oncology factors into that growth? Then, as a related second part: could you either quantify or perhaps rule out the chance of shifting from hotspot testing to panels, purely in terms of the growth available there? Thank you.

Francis deSouza

executive
#34

Yes, of course, David. Let me begin with that. When we came into this year, we noted that the clinical side accounts for slightly less than 50% of our sequencing consumables. Yet we also pointed out that this portion of our business is expanding at a much quicker pace than the research portion. So those two lines ought to intersect, and after they intersect, they will not reverse. Going forward, sequencing consumables tied to the clinical business will make up most of our sequencing consumables, both in dollars and in growth. Within those clinical sequencing consumables, oncology testing for therapy selection is the largest slice of that market. Therefore, we have not — you should anticipate that this will keep going in the future. You have long-term figures for that, but you should anticipate that it remains the largest portion of sequencing tools used in the clinic moving forward. For several reasons, we do anticipate continued movement away from hotspots toward bigger panels, and honestly, not only away from hotspots but also from smaller panels toward bigger panels, and that is propelled by several factors, among them greater adoption of TMB as a biomarker for therapies. So if you consider what occurred with Keytruda, for instance, over the past few months, that keeps building momentum behind the idea that examining gene hotspots alone is insufficient for prescribing a therapy — you also need to examine things such as TMB, and that demands bigger panels. So you factor that in. You factor in what you are observing. When we discussed ASMO, for instance, you are observing momentum and guidelines supporting biomarkers such as TMB; all of this will keep driving momentum toward bigger panels, which will in turn drive additional sequencing and cause oncology testing to expand even more quickly, and thus become a larger piece of sequencing consumable revenue in the future.

Dan Brennan

analyst
#35

Great, thank you for taking my question. Francis, might you provide some insight into what kind of upgrade potential is still out there for those smaller clients who own a HiSeq? I suppose it has been some time since we last discussed that, especially given the reduction in price and what was mentioned this quarter regarding the robust demand you observed on SSE. So any detail on how large that opportunity is, and what do the early tracks appear like during this quarter? And how do you expect that upgrade potential to develop going forward? Thanks.

Francis deSouza

executive
#36

Yes. Perhaps I will begin with a more qualitative perspective, then we can move through it together. So, when we discussed the multi year upgrade opportunity for NovaSeq, there is this subsequent segment that we are now activating, beginning with the Version 1.5 Reagent, which consists of the smaller core labs. Those are the ones that continue to primarily use the HiSeq. And honestly, they have lacked the volume needed to warrant upgrading, since you must have both to realize the advantages tied to the decrease in consumables cost. So 1.5 now alters the economics for them. And that is the portion of the customer base we aim to activate. It has been some time in terms of a number of incidents, so perhaps I will hand it over to you, Sam, to give us some color on that.

Sam Samad

executive
#37

Sure, Dan — on the color, thanks for asking. When it comes to NovaSeq placements, I recall that back when we first introduced NovaSeq, we used to be more specific about how many HiSeq customers we still anticipated would move over to NovaSeq. That said, it's been a while since we offered that detail. What I can share is this: looking at NovaSeq placements so far this year, approximately 40%-ish are still arriving from customers who are new to Illumina. That's genuinely a strong indicator of how NovaSeq has broadened access to sequencing. Another 40% or so is coming by way of NovaSeq capacity upgrades — clearly, these are existing customers simply moving up or adding more capacity. Then there's roughly 20% or so from HiSeq customers who keep making the transition to NovaSeq. That process remains underway, and we expect it to carry on. The V 1.5 upgrade we mentioned should also serve as a catalyst for that, and will fuel it too. So it's still quite encouraging, with solid room to offset.

Juliet Cunningham

executive
#38

Thanks; just a note that you'll be able to hear this call again through the Investor Relations part of our site, and also by following the phone access details included in the earnings release we put out today. We appreciate your participation on today's call. That wraps things up for us; we're eager to share our progress with you when we report the fourth quarter.

Operator

operator
#39

Thank you ladies and gentlemen; this concludes today's conference call. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Illumina, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Illumina, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Illumina, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.